Animal experiment:

Inbred male ACI (180 to 210 g) and LEW (200 to 240 g) rats are used as donors and recipients. Liver transplantation is orthotopically performed. ONO4057 dissolved in 7% NaHCO3 or solvent is administered subcutaneously daily after transplantation. Animals are divided into two groups: group I (n=5), 7% NaHCO3 3 mL/kg as controls; group II (n=6), ONO4057 30 mg/kg per day[2].

ONO4057 is a Leukotriene B4 receptor antagonist, with an IC50 of 0.7±0.3 μM.

Mean animal survivals of the ONO4057-treated animals significantly prolong to 21.0±4.4 days compare with 12.0±0.6 days in control group. Histological findings from grafts taken on day 7 show that severe focal cellular infiltration is observed in both groups, but the degree of hepatocyte necrosis in ONO4057-treated anmimals is milder than that in control group[2].

[1]. Kishikawa K, et al. ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions. Prostaglandins. 1992 Oct;44(4):261-75. [2]. Tanaka M, et al. Effect of leukotriene B(4) receptor antagonist (ONO4057) on hepatic allografting in rats. Transplant Proc. 2000 Nov;32(7):2340.